MedTrace Logo

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

NCT05894876 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-12-12

No results posted yet for this study

Summary

The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy. No medications or other treatments are provided to the participants by Novo Nordisk as part of this study. The study will last for up to 1 year. The participants will attend their usual doctor's appointments. If the participants are not usually visiting the clinic, they will need to do it only once as part of this study. If the participant agrees to take part in the study, they will be asked to read and sign the 'Agreement to take part form'.

Conditions

  • Idiopathic Short Stature

Interventions

OTHER

No treatment is given

No treatment is provided to the participants as part of this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
3 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2025-03-21
Completion
2025-03-21

Countries

  • United States
  • Brazil
  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05894876 on ClinicalTrials.gov